Binnopharm to compete with global drugmakers in Russian hormonal drugs market

21 February 2025

Binnopharm Group, one of Russia’s leading drugmakers, which is controlled by the Russian financial conglomerate AFK Sistema, will begin selling two hormonal drugs in Russia in May 2025, and will consider localizing their production in the future, reports The Pharma Letter’s local correspondent.

That will allow the company to better compete with some global drugmakers in this market segment, according to recent statements by the company’s general director Rustem Muratov. He said in an interview with the Russian Vedomosti business paper, the company is currently actively forming a gynecological portfolio of drugs, which will consist of these and several other drugs.

Rustem Muratov commented: “In the coming year, we plan to introduce at least five products to the Russian market. So far, two drugs for the treatment of endometriosis have already been registered, they will be available for sale in May of this year»

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK